Skip to main content

Advertisement

SpringerLink
Log in

Disease Progression and Pharmacodynamics in Parkinson Disease – Evidence for Functional Protection with Levodopa and Other Treatments

  • Published:
Journal of Pharmacokinetics and Pharmacodynamics Aims and scope Submit manuscript

We have modelled the Unified Parkinson’s Disease Rating Scale (UPDRS) scores collected in 800 subjects followed for 8 years. Newly diagnosed and previously untreated subjects were initially randomized to treatment with placebo, deprenyl, tocopherol or both and, when clinical disability required, received one or more dopaminergic agents (levodopa (carbidopa / levodopa), bromocriptine, or pergolide). Using models for disease progression and pharmacodynamic models for drug effects we have characterized the changes in UPDRS over time to determine the influence of the various drug treatments. We have confirmed and quantitated the relative symptomatic benefits of the dopaminergic agents and provide model-based evidence for slowing of disease progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Fahn S. (1999). Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. Arch. Neurol. 56(5):529–535

    CAS  Google Scholar 

  2. Schulzer M., Mak E., and Calne D.B. (1992). The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann. Neurol. 32(6):795–798

    Article  PubMed  CAS  Google Scholar 

  3. Whone A.L., Watts R.L., Stoessl A.J., Davis M., Reske S., Nahmias C. et al. (2003). Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann. Neurol. 54(1):93–101

    Article  PubMed  CAS  Google Scholar 

  4. Parkinson Study Group. (2002). Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. J. Am. Med. Assoc. 287(13):1653–1661

    Google Scholar 

  5. Davis K.L., Thal L.J., Gamzu E.R., Davis C.S., Woolson R.F., Gracon S.I. et al. (1992). A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer’s disease The Tacrine Collaborative Study Group. N. Engl. J. Med. 327(18):1253–1259

    Article  PubMed  CAS  Google Scholar 

  6. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N. Engl. J. Med. 328:176–183 (1993).

    Google Scholar 

  7. Holford N.H.G., Ludden T. (1994). Time course of drug effect. In: Welling P.G., Balant L.P. (eds) Handbook of Experimental Pharmacology Chapter 11. Springer-Verlag, Heidelberg

    Google Scholar 

  8. Chan P.L.S. and Holford N.H.G. (2001). Drug treatment effects on disease progression. Annu. Rev. Pharmacol. Toxicol. 41:625–659

    Article  PubMed  CAS  Google Scholar 

  9. Holford N.H.G., Kimko H.C., Monteleone J.P., and Peck C.C. (2000). Simulation of clinical trials. Annu. Rev. Pharmacol. Toxicol. 40:209–234

    Article  PubMed  CAS  Google Scholar 

  10. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N. Engl. J. Med. 321:1364–1371 (1989).

    Google Scholar 

  11. Holford N.H.G., Mould D.R., and Peck C.C. (2001). Disease Progress Models. In: Atkinson A. (eds). Principles of Clinical Pharmacology. Academic Press, San Diego, pp. 253–262

    Google Scholar 

  12. Holford N.H.G. and Sheiner L.B. (1981). Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models. Clin. Pharmacokinet. 6:429–453

    Article  PubMed  CAS  Google Scholar 

  13. Holford N.H.G. and Peace K.E. (1992). Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc. Natl. Acad. Sci. USA 89:11466–11470

    Article  PubMed  CAS  Google Scholar 

  14. Pillai G., Gieschke R., Goggin T., Jacqmin P., R.C. Schimmer, and Steimer J.L. (2004). A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. Br. J. Clin. Pharmacol. 58(6):618–631

    Article  PubMed  Google Scholar 

  15. Chan P.L.S., Nutt J.G., and Holford N.H.G. (2005). Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson’s disease. J. Pharmacokinet. Pharmacodyn. 32:459–484

    Article  PubMed  CAS  Google Scholar 

  16. The Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP patients requiring levodopa. Ann. Neurol. 39:37–45 (1996).

    Google Scholar 

  17. The Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP subjects not requiring levodopa. Ann. Neurol. 39:29–36 (1996).

    Google Scholar 

  18. The Parkinson Study Group. Mortality in DATATOP: A multicenter trial in early Parkinson’s disease. Ann. Neurol. 43(3):318–325 (1998).

    Google Scholar 

  19. Shoulson I., Oakes D., Fahn S., Lang A., Langston J.W., LeWitt P. et al. (2002). Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann. Neurol. 51(5):604–612

    Article  PubMed  CAS  Google Scholar 

  20. Beal S.L., Boeckmann A.J., and L. B. Sheiner. NONMEM Project Group. In. NONMEM Users Guides V. Version (ed.). University of California at San Francisco, San Francisco, 1999.

  21. Sheiner L.B. (1997). Learning versus confirming in clinical drug development. Clin. Pharmacol. Ther. 61(3):275–291

    Article  PubMed  CAS  Google Scholar 

  22. Pålhagen S., Heinonen E.H., Hägglund J., Kaugesaar T., Kontants H., Mäki-Ikola O. et al. (1998). Selegiline delays the onset of disability in de novo parkinsonian patients. Neurology 51:520–525

    PubMed  Google Scholar 

  23. Holford N.H.G. (1997). Population models for Alzheimer’s and Parkinson’s disease. In: Aarons L. and Balant L.P. (eds) The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. COST B1 European Commission, Brussels, pp. 97–104

    Google Scholar 

  24. Contin M., Riva R., Martinelli P., Cortelli P., Albani F., and Baruzzi A. (1994). Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson’s disease. Neurology 44:1287–1292

    PubMed  CAS  Google Scholar 

  25. Nutt J.G. and Holford N.H.G. (1996). The response to levodopa in Parkinson’s disease: Imposing pharmacological law and order. Ann. Neurol. 39:561–573

    Article  PubMed  CAS  Google Scholar 

  26. Nutt J.G., Carter J.H., Lea E.S., and Sexton G.J. (2002). Evolution of the response to levodopa during the first 4 years of therapy. Ann. Neurol. 51(6):686–693

    Article  PubMed  CAS  Google Scholar 

  27. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 61(4):561–566 (2004).

    Google Scholar 

  28. Parkinson Study Group. Levodopa and the progression of Parkinson’s disease. N. Engl. J. Med. 351(24):2498–2508 (2004).

    Google Scholar 

  29. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease. J. Am. Med. Assoc. 284(15):1931–1938 (2000).

    Google Scholar 

  30. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., and Lang A.E. (2000). A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 342(20):1484–1491

    Article  PubMed  CAS  Google Scholar 

  31. Mallinckrodt C.H., Clark S.W., Carroll R.J., and Molenbergh G. (2003). Assessing response profiles from incomplete longitudinal clinical trial data under regulatory considerations. J. Biopharm. Stat. 13(2):179–190

    Article  PubMed  Google Scholar 

  32. Hu C. and Sale M.E. (2003). A joint model for nonlinear longitudinal data with informative dropout. J. Pharmacokinet. Pharmacodyn. 30(1):83–103

    Article  PubMed  Google Scholar 

  33. Muenter M.D., and Tyce G.M. (1971). L-dopa therapy of Parkinson’s disease, plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin. Proc. 46:231–239

    PubMed  CAS  Google Scholar 

  34. Clarke C.E., and Davies P. (2000). Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 69(5):590–594

    Article  PubMed  CAS  Google Scholar 

  35. Markham C.H., and Diamond S.G.(1981). Evidence to support early levodopa therapy in Parkinson disease. Neurology 31:125–131

    PubMed  CAS  Google Scholar 

  36. Fahn S. (1996). Is levodopa toxic?. Neurology 47(Suppl 3):S184–S195

    PubMed  CAS  Google Scholar 

  37. Murer M.G., Raisman-Vozari R. and Gershanik O. (1999). Levodopa in Parkinson’s disease: neurotoxicity issue laid to rest? Drug Saf. 21(5):339–352

    Article  PubMed  CAS  Google Scholar 

  38. Agid Y., Chase T., and Marsden D. (1998). Adverse reactions to levodopa: drug toxicity or progression of disease?. Lancet 351(9106):851–852

    Article  PubMed  CAS  Google Scholar 

  39. Murer M.G., Dziewczapolski G., Menalled L.B., Garcia M.C., Agid Y., Gershanik O. et al. (1998). Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann. Neurol. 43(5):561–575

    Article  PubMed  CAS  Google Scholar 

  40. Olanow C.W., Hauser R.A., Gauger L., Malapira T., Koller W., Hubble J. et al. (1995). The effect of deprenyl and levodopa on the progression of Parkinson’s disease. Ann. Neurol. 38:771–777

    Article  PubMed  CAS  Google Scholar 

  41. Hauser R.A., and Holford N.H.G. (2002). Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson’s disease. Mov. Disord. 17(5):961–968

    Article  PubMed  Google Scholar 

  42. Schapira A.H. (2003). Neuroprotection in PD-A role for dopamine agonists?. Neurology 61(6 Suppl 3):S34–42

    PubMed  CAS  Google Scholar 

  43. P. Chan L.S., Nutt J.G., N. Holford H.G., and Parkinson Study Group. Application of clinical trial simulation to evaluate the ELLDOPA trial design. Mov. Disord. 17(5):S111–S112 (2002).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology & Clinical Pharmacology, University of Auckland, Auckland, New Zealand

    Nicholas H. G. Holford & Phylinda L. S. Chan

  2. Dept of Neurology, Oregon Health & Science University, Portland, OR, USA

    John G. Nutt

  3. Dept of Neurology, Parkinson Study Group, Rochester, NY, USA

    Karl Kieburtz & Ira Shoulson

Authors
  1. Nicholas H. G. Holford
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Phylinda L. S. Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John G. Nutt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Karl Kieburtz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ira Shoulson
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Parkinson Study Group

Corresponding author

Correspondence to Nicholas H. G. Holford.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Holford, N.H.G., Chan, P.L.S., Nutt, J.G. et al. Disease Progression and Pharmacodynamics in Parkinson Disease – Evidence for Functional Protection with Levodopa and Other Treatments. J Pharmacokinet Pharmacodyn 33, 281–311 (2006). https://doi.org/10.1007/s10928-006-9012-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10928-006-9012-6

Keywords

Search

Navigation